Pharmaids Pharmaceuticals Reports Mixed Financial Results Amidst Rising Costs and Strong Sales Growth in March 2025

Pharmaids Pharmaceuticals has recently reported its financial results for the quarter ending March 2025, revealing a complex picture of performance within the microcap pharmaceuticals and biotechnology sector. The company's net sales for the latest six months reached Rs 9.48 crore, reflecting a notable year-on-year growth of 62.61%. This positive sales trend indicates a strong demand for its products in the near term. However, the financial results also highlight significant challenges. The Profit After Tax (PAT) for the quarter was recorded at Rs -4.00 crore, which represents a decline compared to the average PAT of the previous four quarters. Similarly, the Profit Before Tax (PBT) stood at Rs -5.53 crore, also showing a decrease relative to past performance. Additionally, the interest expense surged to Rs 1.01 crore, marking a substantial increase that suggests heightened borrowing costs. In light of these developments, Pharmaids Pharmaceuticals has experienced an adjustment in its evaluation, with its score reflecting the current financial landscape. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.